Spyre Therapeutics, Inc. (SYRE)
SYRE Stock Price Chart
Explore Spyre Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze SYRE price movements and trends.
SYRE Company Profile
Discover essential business fundamentals and corporate details for Spyre Therapeutics, Inc. (SYRE) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
7 Apr 2016
Employees
73.00
Website
https://www.spyre.comCEO
Cameron Turtle DPHIL,
Description
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
SYRE Financial Timeline
Browse a chronological timeline of Spyre Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.75.
Earnings released on 5 Aug 2025
EPS came in at -$0.49 surpassing the estimated -$0.73 by +32.88%.
Earnings released on 8 May 2025
EPS came in at -$0.74 surpassing the estimated -$0.76 by +2.63%.
Earnings released on 27 Feb 2025
EPS came in at -$0.81 surpassing the estimated -$0.89 by +8.99%.
Earnings released on 7 Nov 2024
EPS came in at -$1.36 falling short of the estimated -$0.80 by -70.00%.
Earnings released on 7 Aug 2024
EPS came in at -$0.86 surpassing the estimated -$0.90 by +4.44%.
Earnings released on 9 May 2024
EPS came in at -$1.20 falling short of the estimated -$0.90 by -33.33%.
Earnings released on 29 Feb 2024
EPS came in at -$2.28 falling short of the estimated -$0.48 by -375.00%, while revenue for the quarter reached $1.04M , beating expectations by +373.64%.
Earnings released on 9 Nov 2023
EPS came in at -$9.34 falling short of the estimated -$0.84 by -1.01K%.
Stock split effective on 8 Sept 2023
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 11 Aug 2023
EPS came in at -$1.66 surpassing the estimated -$4.50 by +63.11%, while revenue for the quarter reached $688.00K , beating expectations by +247.47%.
Earnings released on 31 Mar 2023
EPS came in at -$4.89 falling short of the estimated -$4.50 by -8.57%, while revenue for the quarter reached $198.00K , beating expectations by +7.61%.
Earnings released on 30 Dec 2022
EPS came in at -$7.20 falling short of the estimated -$5.71 by -26.14%, while revenue for the quarter reached $168.00K , beating expectations by +26.00%.
Earnings released on 29 Sept 2022
EPS came in at -$4.84 surpassing the estimated -$6.25 by +22.57%, while revenue for the quarter reached $174.00K , missing expectations by -16.48%.
Earnings released on 29 Jun 2022
EPS came in at -$6.79 surpassing the estimated -$7.95 by +14.57%, while revenue for the quarter reached $625.00K , missing expectations by -11.91%.
Earnings released on 30 Mar 2022
EPS came in at -$9.26 , while revenue for the quarter reached $1.36M .
Earnings released on 30 Dec 2021
EPS came in at -$10.36 falling short of the estimated -$8.54 by -21.33%, while revenue for the quarter reached $3.64M , beating expectations by +128.84%.
Earnings released on 29 Sept 2021
EPS came in at -$7.72 , while revenue for the quarter reached $1.40M .
Earnings released on 29 Jun 2021
EPS came in at -$2.60 , while revenue for the quarter reached $13.70M .
Earnings released on 31 Mar 2021
EPS came in at -$6.94 .
Earnings released on 31 Dec 2020
EPS came in at -$9.47 .
Earnings released on 30 Sept 2020
EPS came in at -$7.24 .
SYRE Stock Performance
Access detailed SYRE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.